Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

36.94USD
2:29am IST
Change (% chg)

$-0.05 (-0.14%)
Prev Close
$36.99
Open
$37.24
Day's High
$37.28
Day's Low
$36.50
Volume
6,836,485
Avg. Vol
5,174,129
52-wk High
$37.37
52-wk Low
$30.90

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $214,682.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.55

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Kite Announces Clinical Collaboration With Pfizer

* KITE ANNOUNCES CLINICAL COLLABORATION TO EVALUATE INVESTIGATIONAL COMBINATION OF YESCARTA™ (AXICABTAGENE CILOLEUCEL) AND PFIZER’S UTOMILUMAB IN LARGE B-CELL LYMPHOMA

18 Jan 2018

BRIEF-Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio

* FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO

16 Jan 2018

BRIEF-Novartis poaches Pfizer oncology head Elizabeth Barrett

* Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the Executive Committee of Novartis, effective February 1, 2018

11 Jan 2018

BRIEF-Basilea Announces Completion Of License Agreement Extension With Pfizer

* BASILEA ANNOUNCES COMPLETION OF THE LICENSE AGREEMENT EXTENSION WITH PFIZER FOR ANTIFUNGAL CRESEMBA FOR CHINA AND ASIA PACIFIC Source text for Eikon: Further company coverage: (Gdynia Newsroom)

10 Jan 2018

GSK CEO says looking at Pfizer consumer business, but not a priority

GlaxoSmithKline's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc's consumer products business, but would not overpay for the asset.

10 Jan 2018

GSK CEO says looking at Pfizer consumer business, but not a priority

GlaxoSmithKline's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc's consumer products business, but would not overpay for the asset.

10 Jan 2018

GSK CEO says looking at Pfizer consumer business, but not a priority

Jan 9 GlaxoSmithKline's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc's consumer products business, but would not overpay for the asset.

10 Jan 2018

Pfizer ends research for new Alzheimer's, Parkinson's drugs

NEW YORK Pfizer Inc is abandoning research to find new drugs aimed at treating Alzheimer's and Parkinson's disease, the U.S. pharmaceutical company announced on Saturday.

09 Jan 2018

Pfizer ends research for new Alzheimer's, Parkinson's drugs

(In this January 7 story corrects paragraph 3 to show that tanezumab is not yet on the market)

09 Jan 2018

CORRECTED-Pfizer ends research for new Alzheimer's, Parkinson's drugs

NEW YORK, Jan 7 Pfizer Inc is abandoning research to find new drugs aimed at treating Alzheimer's and Parkinson's disease, the U.S. pharmaceutical company announced on Saturday.

09 Jan 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $147.36 +0.44
Novartis AG (NOVN.S) CHF83.38 +0.48
Merck & Co., Inc. (MRK.N) $61.28 +0.15
Roche Holding Ltd. (ROG.S) CHF234.50 +1.30
Roche Holding Ltd. (RO.S) CHF237.80 +1.00
Abbott Laboratories (ABT.N) $59.31 +0.24
Bayer AG (BAYGn.DE) €104.08 +0.60
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €72.95 +0.58
AstraZeneca plc (AZN.L) 5,043.00 +62.50

Earnings vs. Estimates